ERBB2 and breast cancer: This partly supports previous findings by Eggeman et al. (n = 5907) and Rossi et al. (n = 1150) [18, 19], where patients with HER2 IHC 2+ ISH− early BC had worse DFS than those with HER2 IHC 0 or 1+.